Intellia Therapeutics Inc buy Barclays PLC
Start price
28.02.25
/
50%
€9.82
Target price
28.02.26
€25.05
Performance (%)
-22.03%
Price
08:01
€7.66
Summary
This prediction is currently active. The prediction for Intellia Therapeutics Inc disappoints with a performance of -22.03%. This prediction currently runs until 28.02.26. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Intellia Therapeutics Inc | -4.303% | -4.303% |
| iShares Core DAX® | 0.795% | 1.458% |
| iShares Nasdaq 100 | -3.088% | -0.762% |
| iShares Nikkei 225® | -0.952% | -2.268% |
| iShares S&P 500 | -1.393% | 0.199% |
Comments by Barclays_PLC for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Barclays PLC from $55.00 to $26.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Barclays_PLC for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€8.12
07.11.25
07.11.25
€12.13
07.11.26
07.11.26
-5.67%
08:01
08:01
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€15.58
08.11.24
08.11.24
€51.38
08.11.25
08.11.25
-41.87%
09.11.25
09.11.25
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€36.00
04.08.23
04.08.23
€81.52
04.08.24
04.08.24
-40.22%
05.08.24
05.08.24